Third Age Health Services (TAH) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
16 Jun, 2026Executive summary
Net profit after tax (NPAT) increased 32% year-over-year to $1,520k for the six months ended 30 September 2025, and 14% over 2H25.
Underlying NPATA rose 28% year-over-year to $1,742k and 14% over the previous half-year period.
Acquisitions of ARC Health and Cicada Health expanded the national network, were immediately accretive, and contributed to patient population growth.
Services expanded to 122 aged residential care facilities, up 35% YoY, with ARC residents served rising 35.6% YoY to 7,159.
Combined enrolled patient population grew 5% YoY to 27,191, including acquisitions.
Financial highlights
Total revenue grew 13.2% year-over-year to $10,653k and 10% over 2H25.
Revenue from ARC-related business up 20% YoY to $6,840k.
EBITDA increased to $2,759k from $2,253k year-over-year.
Underlying EBIT up 24% YoY to $2,539k; EBIT margin improved to 23.8%.
Basic and diluted EPS rose to 14.22 cents from 10.26 and 9.96 cents, respectively.
Outlook and guidance
Continued focus on customer satisfaction, operational discipline, and long-term durability.
Ongoing investment in workforce recruitment and digital infrastructure to support future growth.
Board adopted a fixed quarterly dividend policy of 4 cents per share, with second quarter fully imputed dividend per share of 4.00 cents declared, totaling 8.00 cents for 1H26.
Latest events from Third Age Health Services
- NPAT up 115% to $1,154k, with strong revenue, margin, and patient growth.TAH
H1 202516 Jun 2026 - Underlying NPATA up 69% and revenue up 26%, with strong growth in ARC and General Practice.TAH
H2 202516 Jun 2026 - Q3 FY26 revenue up 23.3% YoY, underlying NPATA up 22.1%, 4.00 cent dividend declared.TAH
Q3 2026 TU16 Jun 2026 - Revenue up 17.9% YoY, underlying NPATA up 25.9%, and total FY26 dividends at 16.00 cents.TAH
H2 202616 Jun 2026 - Statutory NPAT surged 236% to $1.38m on 35% revenue growth, with strong ARC expansion.TAH
H2 202415 May 2026 - Q3 FY25 saw strong profit growth, margin expansion, higher dividends, and robust patient gains.TAH
Q3 2025 TU10 Dec 2025 - Strong profit growth and a new fixed dividend policy highlight robust Q1 FY26 performance.TAH
Q1 2026 TU28 Jul 2025 - Revenue and profit surged in Q1 FY25, supported by acquisitions and patient growth.TAH
Q1 2025 TU13 Jun 2025